Skip to main content

Advertisement

Table 2 Subgroup analysis for overall survival in cancer patients with higher MDSCs

From: Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis

Subgroup analysis No. of studies No. of patients Pooled HR(95%CI) Heterogeneity
Fixed Random I2 p-value
Region
 Eastern 13 936 2.47 (1.95,3.12) 2.47 (1.95,3.12) 0% 0.892
 Western 6 521 1.35 (1.18,1.54) 2.37 (1.41,3.97) 75.8% 0.001
Sample size
 <50 7 225 2.67 (1.85,3.84) 2.67 (1.85,3.84) 0% 0.786
 ≥50, < 100 9 680 2.26 (1.78,2.88) 2.37 (1.78,3.14) 18.9% 0.275
 ≥100 3 552 1.27 (1.11,1.46) 2.04 (0.95,4.37) 74.5% 0.020
Cancer types
 GI cancers 8 631 1.36 (1.20,1.55) 1.92 (1.36,2.72) 54.2% 0.033
 HCC 3 367 2.41 (1.53,3.82) 2.41 (1.53,3.82) 0% 0.965
 NKT 2 64 6.02 (1.70,21.28) 6.02 (1.70,21.28) 0% 0.670
 Melanoma 3 214 2.24(1.50,3.35) 3.87 (1.24,12.04) 73.9% 0.022
 Other types 3 181 3.07 (1.91,4.92) 3.07 (1.91,4.92) 0% 0.912
Subtypes
 Total-MDSCs 10 765 1.40 (1.23,1.60) 2.53 (1.63,3.94) 68.4% 0.001
 PMN-MDSCs 5 487 2.32 (1.73,3.13) 2.32 (1.73,3.13) 0% 0.912
 Mo-MDSCs 4 205 2.08 (1.40,3.11) 2.95 (1.34,6.51) 45.9% 0.136
Cut-off value
 <10 14 1024 1.46 (1.29,1.66) 2.56 (1.79,3.67) 64.3% 0.001
 ≥10 5 433 2.23 (1.67,2.98) 2.23 (1.67,2.98) 0% 0.527
NOS score
 <7 10 901 2.59 (2.02,3.31) 2.59 (2.02,3.31) 0% 0.770
 ≥7 9 556 2.17 (1.45,3.25) 1.36 (1.19,1.55) 60.5% 0.009